Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director Srinivas Akkaraju purchased 159,920 shares of Alumis stock in a transaction that occurred on Friday, May 2nd. The shares were bought at an average price of $4.55 per share, for a total transaction of $727,636.00. Following the completion of the transaction, the director now owns 3,426,418 shares in the company, valued at $15,590,201.90. The trade was a 4.90 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Srinivas Akkaraju also recently made the following trade(s):
- On Monday, May 5th, Srinivas Akkaraju acquired 160,370 shares of Alumis stock. The shares were bought at an average cost of $4.67 per share, with a total value of $748,927.90.
Alumis Trading Down 1.1 %
Shares of NASDAQ ALMS opened at $4.35 on Wednesday. Alumis Inc. has a 1 year low of $3.18 and a 1 year high of $13.53. The company's 50-day moving average is $5.40 and its 200 day moving average is $7.34.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on ALMS. Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They set an "outperform" rating and a $32.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Alumis in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $25.86.
Check Out Our Latest Research Report on ALMS
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after purchasing an additional 2,949 shares during the period. Wells Fargo & Company MN raised its holdings in Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after purchasing an additional 3,823 shares in the last quarter. Northern Trust Corp lifted its position in Alumis by 4.3% during the fourth quarter. Northern Trust Corp now owns 111,326 shares of the company's stock valued at $875,000 after buying an additional 4,587 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Alumis by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company's stock valued at $891,000 after buying an additional 4,808 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Alumis by 33.9% in the 4th quarter. Barclays PLC now owns 24,581 shares of the company's stock worth $193,000 after buying an additional 6,221 shares during the period.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
